Although one of the top investment themes of 2023 was artificial intelligence (AI), there were several other serious contenders. The weight-loss market has emerged as a hot growth area, with diabetes and obesity treatments on the rise -- and the majority of top-branded medications are developed by just two companies.

Let's take a closer look at this duo in the pharmaceutical industry that are dominating the weight-loss market and assess why each stock presents an intriguing long-term buying opportunity.

If you aren't familiar with Novo Nordisk (NYSE: NVO), odds are you've seen the commercials or heard the catchy jingles for its various weight-loss medications. Novo Nordisk is a Danish pharmaceutical company and the developer behind Ozempic, Wegovy, Rybelsus, and Saxenda.

Continue reading

Source Fool.com